ClinicalTrials.gg
CompletedNCT00653913Updated Feb 16, 2022

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

A Phase 1 interventional study of SCH 58235 and pitavastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to male participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Organon and Co · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
93rd of 97
18 · median 148
Started
2004
with 5 others
Phase 1
6 of 98
none open now
Registered
33rd of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 93rd largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2004, is one of 6 in phase 1, and was the 33rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study was designed to evaluate the pharmacokinetic interaction and safety of coadministration of SCH 58235 (ezetimibe) and pitavastatin in healthy Japanese adult male subjects or adult male subjects having no obvious disease other than high cholesterol levels.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male subjects meeting all the criteria below or adult male subjects having no obvious disease other than high cholesterol levels.
  • Aged 20 years or over and 65 years or below when the is obtained.
  • Weighing 50 kg or over and 80 kg or below on the day of the screening tests, with [Body Mass Index: body weight (kg)/height (m)2] ranging from 16.5 to 27.5.

Exclusion criteria

Exclusion Criteria:

Patients meeting any one of the following conditions are excluded from the study.

  • Subjects with the triglyceride value at screening test exceeding 500 mg/dL.
  • Subjects with past history of drug allergy (shock, anaphylactic symptom, and angioedema).
  • Subjects with past history of alcohol or drug dependence.
  • Subjects with past history of mental disorder.
  • Subjects positive in the test for HBs antigen, antibody, or antibody or in the serological test for syphilis.
  • Subjects who used any drug within 2 weeks of product administration in Period 1.
  • Subjects who have drawn more than 400 mL of blood within 12 weeks before administration day in Period 1.
  • Subjects who participated in other study within 16 weeks of investigational product administration in Period 1 and was administered a investigational product.
  • Subjects who cannot take measures during the study period (from providing to completion of Period 3 examination)
  • Subjects who the investigator judges are inappropriate to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Group A

    SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

  • Active comparator
    Group B

    SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

  • Active comparator
    Group C

    Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

  • Active comparator
    Group D

    Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

  • Active comparator
    Group E

    Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

  • Active comparator
    Group F

    Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)

    Drug: SCH 58235 · Drug: pitavastatin

Interventions

  • SCH 58235 10 mg (once daily)

    Also known as: Ezetimibe

  • Pitavastatin 2 mg (once daily)

06

What researchers measure

Primary outcomes

  1. Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin after administration of each drug alone and in combination, using Cmax and AUC(0-24h).

    Time frame: Day 7 of each period

Secondary outcomes

  1. Compare plasma concentrations of SCH 58235 (ezetimibe) and pitavastatin administration of each drug alone and in coadministration, using Tmax, plasma concentration 24 h after last dose, and AUC(I).

    Time frame: Day 7 of each period

  2. Adverse events, laboratory tests results, and vital signs.

    Time frame: Throughout study

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Sep 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 7, 2008
Start
Mar 2004
Primary completionActual
Sep 2004
CompletionActual
Sep 2004
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00653913
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Mar 2004
Primary completion
Sep 2004
Completion
Sep 2004
Last update
Feb 16, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Pitavastatin

Start the discussion